Radient Pharmaceuticals Corporation fka RXPC

[livinginsv]

provista's method . . .

Methods: We have conducted two independent, multi-center, prospective clinical trials to establish the clinical validity of a breast cancer biomarker assay that uses a combination of Serum Protein Biomarkers (SPB), Tumor-Associated Autoantibodies (TAAb) with patient specific data to differentiate patients with benign breast disease from those with invasive breast cancer (IBC)

no DR-70 here either . . . and no presentation at ASCO, just a paper included in the ASCO docs . . . not good . . .

JT, how can ADI be a subsidiary of a non-existent corporation? . . .